European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
Merck & Co. (NYSE: MRK) Delayed: 117.72 +2.24 (1.94%)
Previous Close $115.48    52 Week High $65.46 
Open $116.53    52 Week Low $47.97 
Day High $118.83    P/E 80.08 
Day Low $116.53    EPS $1.47 
Volume 2,559,679